This phase I/II study is evaluating how safe and effective a new targeted therapy (BGB-11417) is alone, and in combination with the targeted therapy carfilzomib and the steroid dexamethasone, in people with relapsed/refractory multiple myeloma.
This trial is treating patients with relapsed/refractory multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
BeiGene Australia Pty Ltd
This study consists of two parts. Part 1 involves dose escalation and de-escalation to determine the maximum tolerated dose (MTD) of BGB-11417. Part 2 involves a cohort expansion with 5 expansion cohorts to further evaluate the safety and efficacy of BGB-11417 as monotherapy, and in combination with dexamethasone and carfilzomib. BGB-11417 will be administered orally daily. Dexamethasone will be administered once weekly either orally or intravenously. Carfilzomib will be administered intravenously weekly.
Recruiting Hospitals Read More